advancing negotiations

Geoff is really controling his enthusiasm:

As we advance negotiations for new licensing agreements for
Mix&Go, protecting its value in this large and strategically important market is paramount.

Paramount in this context reads as condition to advance any further.


The application for Australia, additional applications on the way are a very positive developments.

This part seems to be directly a consequence of the fact that our technology is now tested for a whole pipeline of one of the major IVD companies :

A different version may be more effective in developing
more efficient systems from water purification to purification of new protein drugs. Additional patents
have been filed to extend the protection offered over Mix&Go.

This leads one straight to the assumption that new drug developments within one of the major IVD's is pushing this deal ahead.
Protein drugs are commonly used for neurological diseases.
See research about toxic beta amyloid protein which is responsible for clogging several cell-transport motors necessary for cell division.

This blockage leads to the abnormal cell division and defective neurons associated with the disease.

This leads me straight back to Evotec and the recently signed deal with Roche.


This update is the strongest link so far in speculating that we are indeed partnering with Roche for the IVD market.